Medscape: FDA Pushes for Buprenorphine Labeling Changes to Facilitate Higher Doses
The FDA noted that a Reagan-Udall Foundation public meeting in the spring of 2023 — with FDA and the Substance Abuse and Mental Health Services Administration (SAMHSA) — and a December 2023 meeting with FDA, SAMHSA, and the National Institute on Drug Abuse helped shed more light on the ongoing barriers to the use of higher dosages. The FDA labeling was determined to be one of the biggest impediments.